These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 8611049

  • 1. [Current problems in development of new anticancer agents for new molecular targets].
    Nishii K.
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):211-8. PubMed ID: 8611049
    [Abstract] [Full Text] [Related]

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 3. Anticancer Drug Development: The Way Forward.
    Connors T.
    Oncologist; 1996 Dec; 1(3):180-181. PubMed ID: 10387985
    [Abstract] [Full Text] [Related]

  • 4. The interaction of oncogene and tumour suppressor gene defects with cytotoxic drugs: its role in the improvement of selective toxicity and the development of new drugs in clinical oncology.
    Petty RD.
    Clin Oncol (R Coll Radiol); 1996 Dec; 8(3):186-9. PubMed ID: 8814375
    [No Abstract] [Full Text] [Related]

  • 5. Strategy for the development of novel anticancer drugs.
    Saijo N, Tamura T, Nishio K.
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
    Rixe O, Fojo T.
    Clin Cancer Res; 2007 Dec 15; 13(24):7280-7. PubMed ID: 18094408
    [Abstract] [Full Text] [Related]

  • 15. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
    Raymond E, Faivre S, Dieras V, Von Hoff D.
    Bull Cancer; 1997 Dec 15; 84(12):1123-33. PubMed ID: 9587365
    [Abstract] [Full Text] [Related]

  • 16. [Preclinical studies for development of anti-cancer drugs: current and historical status and problems].
    Okabe M, Kobayashi S, Hirata T, Nakano H, Ikegami J, Inoue K, Komuro T.
    Gan To Kagaku Ryoho; 1994 Oct 15; 21 Suppl 3():302-9. PubMed ID: 7986108
    [Abstract] [Full Text] [Related]

  • 17. [Problems associated with molecular targeted drugs for cancer].
    Kawaishi M, Koizum F, Nishio K.
    Gan To Kagaku Ryoho; 2006 Oct 15; 33(10):1373-9. PubMed ID: 17033223
    [Abstract] [Full Text] [Related]

  • 18. New anticancer agents: in vitro and in vivo evaluation.
    Zips D, Thames HD, Baumann M.
    In Vivo; 2005 Oct 15; 19(1):1-7. PubMed ID: 15796152
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Epigenome-derived drugs: recent advances and future perspectives.
    Vogiatzi P, Aimola P, Scarano MI, Claudio PP.
    Drug News Perspect; 2007 Dec 15; 20(10):627-33. PubMed ID: 18301797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.